8-K: Seer Inc. Reports Mixed Q4 Results but Sees Growth in 2024

Seer Inc. announced its fourth quarter and full year 2023 financial results, showing a slight decrease in Q4 revenue but an overall increase for the year, along with a positive outlook for 2024.

Summary

• Seer Inc. reported a revenue of $4.4 million for the fourth quarter of 2023, which is a 4% decrease compared to the same period in 2022.
• The full year 2023 revenue reached $16.7 million, an 8% increase compared to 2022.
• The company shipped 23 instruments in 2023, bringing the total to 62.
• Seer expanded its international reach by adding four new distributors and partners.
• The first peer-reviewed customer publication was released in Nature Communications, highlighting the capabilities of the Proteograph platform.
• The Protein Discovery Catalog was launched, featuring over 10,000 proteins across 1,900 pathways.
• Seer ended the year with approximately $373 million in cash, cash equivalents, and investments.
• Gross profit for Q4 2023 was $2.0 million with a gross margin of 45.1%.
• Operating expenses for Q4 2023 were $24.2 million, a decrease of 11% compared to the same period in 2022.
• The net loss for Q4 2023 was $17.8 million, an improvement from the $22.5 million loss in Q4 2022.
• Gross profit for the full year 2023 was $8.5 million with a gross margin of 51.1%.
• Operating expenses for the full year 2023 were $112.0 million, compared to $104.3 million in 2022.
• The net loss for the full year 2023 was $86.3 million, an improvement from the $93.0 million loss in 2022.
• Seer anticipates full year 2024 revenue to be between $18 million and $20 million, representing a 14% growth at the midpoint.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the revenue growth, improved net loss, and positive outlook for 2024, but tempered by the decrease in Q4 revenue and ongoing losses.

Positives

• Full year revenue increased by 8% year-over-year.
• The company saw a reduction in operating expenses in Q4 2023.
• Net losses improved for both the quarter and the full year.
• Seer has a strong cash position with approximately $373 million in cash, cash equivalents, and investments.
• The company is expanding its international presence with new distributors and partners.
• The Proteograph platform is gaining recognition with a customer publication in Nature Communications.
• The launch of the Protein Discovery Catalog enhances the platform's capabilities.

Negatives

• Fourth quarter revenue decreased by 4% compared to the same period in 2022.
• The decrease in Q4 revenue was primarily due to a decrease in lease revenue related to SP100 instruments.
• The company continues to operate at a loss, with a net loss of $86.3 million for the full year 2023.
• Related party revenue makes up a significant portion of total revenue.

Risks

• The company's revenue is still heavily reliant on related party transactions.
• The company is still operating at a loss, and it is not clear when it will become profitable.
• The company's future success depends on the widespread commercial adoption of its Proteograph platform.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Seer expects full year 2024 revenue to be in the range of $18 million to $20 million, representing growth of 14% at the midpoint over full year 2023.

Management Comments

• Omid Farokhzad, Chair and CEO, stated that customers continue to demonstrate the powerful biological insight possible with the Proteograph Product Suite.
• Omid Farokhzad also mentioned that the company is focused on translating the platform's performance into widespread commercial adoption.
• The CEO expressed confidence in the substantial long-term opportunity ahead.

Industry Context

Seer operates in the competitive life sciences and proteomics market, where companies are developing advanced tools for biological research and drug discovery. The publication of customer data in Nature Communications is a positive sign for the company's technology and its potential impact on the field.

Comparison to Industry Standards

• Seer's revenue growth of 8% for the full year is moderate compared to some high-growth biotech companies, but it is a positive sign given the early stage of commercialization.
• The gross margin of 51.1% for the full year is relatively healthy for a company in the life sciences sector, indicating good pricing power.
• The company's operating expenses are still high, which is typical for a company investing heavily in research and development.
• The net loss of $86.3 million for the full year is significant, but it is an improvement from the previous year, suggesting progress towards profitability.
• Companies like Quanterix and SomaLogic, which also focus on proteomics, are key competitors. Quanterix reported a 2023 revenue of $130.5 million, while SomaLogic reported $105.7 million, both significantly higher than Seer's $16.7 million. However, these companies are more mature and have a larger installed base.

Related Party Transactions

• Related party revenue was $366 thousand in Q4 2023 and $4.4 million for the full year 2023.
• Related party service revenue was $201 thousand in Q4 2023 and $241 thousand for the full year 2023.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and improved net loss, but concerned about the ongoing losses and reliance on related party revenue.
• Employees may be positively impacted by the company's growth and expansion.
• Customers may benefit from the continued development and commercialization of the Proteograph platform.
• Suppliers may see increased demand for their products and services as the company grows.

Next Steps

• Seer will host a conference call to discuss the fourth quarter and full year 2023 financial results on February 29, 2024.
• The company will continue to focus on translating the performance of its platform into widespread commercial adoption.
• Seer will provide updates on its progress throughout 2024.

Key Dates

Keywords

proteomics, life sciences, Proteograph, revenue, financial results, instrument sales, protein analysis, biotechnology, research, diagnostics